This web only provides the extract of this article. If you want to read the figures and tables, please reference the PDF full text on Blackwell Synergy. Thank you.
- Clinical Experience -
Evaluation of an alternative dosing regimen with tadalafil,
three times per week, for men with erectile dysfunction: SURE study in Italy
Vincenzo Mirone1, Ciro
Imbimbo1, Andrea Rossi2, Riccardo
Sicuteri2, Domenico Valle2, Nicola Longo, Ferdinando
Fusco, Italian SURE Study Group*
1Department of Urology, University Federico II of Naples, Naples 80132, Italy
2Ely Lilly Italy, Florence 50019, Italy
Abstract
Aim: To examine the preference for two dosing regimens of 20 mg of tadalafil, on demand or three times per week,
in men affected with erectile dysfunction (ED) in
Italy. Methods: Scheduled Use versus on demand Regimen
Evaluation (SURE) is a multicenter, crossover and open-label study, involving 94 urology centers in Italy. Patients aged
18 years or older affected with ED for at least 3 months were enrolled and randomized to 20 mg of tadalafil treatment
on demand or three times per week for 5_6 weeks. After a 1-week washout, patients were crossed over to the
alternate regimen for 5_6 weeks. A treatment preference question was used to determine the preferred treatment
regimen. International Index of Erectile Function (IIEF) and Sexual Encounter Profile (SEP) questionnaire were used
as efficacy measures. Results: A total of 1 058 men (mean age 54.8 years), were randomized to treatment. Overall,
59.1% of patients preferred the on-demand regimen and 41.9% preferred the three times per week dosing. Both
regimens were efficacious and well tolerated. Although a statistically higher improvement of the IIEF erectile function
(IIEF-EF) domain score and the SEP questionnaire was reported for the three times per week compared to the
on-demand treatment regimen, this difference was numerically minimal and lacking in clinical
significance. Conclusion:
Tadalafil is effective and well tolerated whether used on demand or three times per week. Patients should be given the
option to choose the best treatment regimen according to personal needs and
preferences. (Asian J Androl 2007 May; 9: 395_402)
Keywords: erectile dysfunction; SURE study; on demand; three times per week; alternate; tadalafil
Correspondence to: Dr Ferdinando Fusco, Urologic Clinic, University Federico II of Naples, Via S. Pansini, Naples 5-80132, Italy.
Tel: +39-081-7462-611 Fax: +39-081-5452-959
E-mail: ferdinando-fusco@libero.it
Received 2006-06-08 Accepted 2006-06-15
*The italian Scheduled Use versus on demand
Regimen Evaluation (SURE) Study Group:
Vincenzo Mirone (Coordinating Investigator), G. Alei, G. Anselmo, M.
Aquilini, C. Bellorofonte, A. Bonno, M. Boscaro, W.
Bozzo, G. Breda, M. M. Caotorta, C. Carani, A. Casarico,
V. Cassutti, M. Cecchi, V. Cicalese, G. Comeri, M.
Cordari, L. Cormio, G. D'Agata, O. D'Alia, C. De Dominicis, G. De Grande, U. Di Mario, A. Di Rienzo, G.
Fasolis, C.B. Fasolo, D. Fedele, V. Ferrara, C. Foresta,
G. Forti, S. Francavilla, B. Frea, S. Genovese, V. Gentile,
E. Ghigo, O. Giampietro, C. Imbimbo, U. Jacobellis, B.
Jandolo, E. Jannini, G. La Pera, A. Lembo, A. Lenzi, G.
Ludovico, E. Macchia, A. Maffucci, G. Maio, G. Malossini,
F. Mantero, A. Marin, G. Mazza, F. Mazzarella, F. Menchini-Fabris, F. Montorsi, G. Morrone, G. Muzzonigro,
A. Nasta, G. Nicita, C. Nobile,A. Pagano, R. Paolini, M.
Paradiso, C. Pavone, E. Pescatori, P. Pittaluga, F. Poletti,
A. Pontiroli, M. Porena, C. Provenzano, A. Pycha, S.
Ranno, M. Ruggeri, P. Scarano, R. M. Scarpa, L. Scionti,
C. Selli, A. Serao, V. Sidari, F. Sorrentino, E. Spera, G.
Spera, G. Strada, A. Tasca, P. Tatti, V. Toscano, R.
Trevisan, A. Trinchera, P. Turchi, E. Usai, D. Vecchio, G.
A. Ventrice, A. Vita, R. Volpi and T. Zenico.
DOI: 10.1111/j.1745-7262.2007.00214.x
1 Introduction
Tadalafil is an effective and well tolerated
phosphodiesterase type 5 (PDE5) inhibitor, approved in more than
100 countries for the treatment of erectile dysfunction
(ED). Compared to sildenafil citrate and vardenafil HCL,
tadalafil presents unique pharmacokinetic properties, as
it has been shown to be effective up to 36 hours from
dosing [1]. This characteristic has opened new
therapeutic possibilities in the treatment of ED with respect to
other shorter half-life PDE5 inhibitors that allow patients
to engage in sexual intercourse within a few hours of
dosing. Using traditional "on-demand" dosing, the
long-lasting effectiveness of tadalafil allows patients to
engage in sexual intercourse far after dosing, reducing the
need for strictly planning sexual activity [2].
Furthermore, dosing of tadalafil on a regular basis has
been evaluated. The Scheduled Use versus on demand
Regimen Evaluation (SURE) study, including more than 4
000 patients in 14 European countries, has demonstrated
that a three-time per week regimen of tadalafil is as
affective and well tolerated as the on-demand regimen and that
more than 42.2% of patients prefer the fixed dosing
treatment when allowed to choose [3]. However, the pattern
of choice was independent of patients' baseline characteristics, like ED severity and etiology and the
reasons for preference were related to individual cultural and
psychosocial factors, which might differ among countries.
We analyzed the Italian data subset of the SURE study to
evaluate the efficacy and safety of a fixed dosing
treatment with 20 mg of tadalafil and to determine patient
preference for an on-demand or a three-time per week regimen.
2 Materials and methods
SURE was a randomized, crossover and open-label
study, involving 94 urology centers in Italy from
October 2002 to July 2003. Patients were included if aged at
least 18 years and affected with ED of any severity and
etiology for at least 3 months. Patients had to be
engaged in a stable heterosexual relationship throughout the
study period and had to agree not to use any other ED
treatment from the beginning of the run-in period to
96 hours after the final visit. Exclusion criteria were:
use of nitrates, cancer chemotherapy or antiandrogens
and congestive hearth failure. Notably, patients
previously assuming other commercially available PDE5
inhibitors were not excluded from the study.
The study design (Figure 1) has already been
described in detail [2]. Briefly, after signing an informed
consent, each patient underwent a screening evaluation,
including a comprehensive review of medical history,
physical examination, laboratory safety tests and electrocardiogram, and started a 3_4 week run-in,
treatment-free period phase. Patients were then randomized
to assume 20 mg of tadalafil according to either a
"on-demand" or "three times per week" regimen for
5_6 weeks (Treatment I). Patients did not have to observe
any restriction on food or alcohol. Patients randomized
to the "on-demand" regimen were instructed not to
exceed one dose per day. Patients randomized to the "three
times per week" regimen were instructed to assume
20 mg of tadalafil on Monday, Wednesday and Friday
(subgroup A) or on Tuesday, Thursday and Saturday (subgroup B) at the same hour, independently of sexual
activity. After a 1-week washout period, patients were
switched to the other treatment regimen for 5_6 weeks
(Treatment II), in a cross-over fashion. At the
completion of the second treatment phase, patients were asked
to choose the treatment regimen for the extension phase,
which was for a required duration of at least 14 days.
Efficacy measures were the International Index of
Erectile Function (IIEF) and the Sexual Encounter
Profile (SEP) questionnaires, collected for each patient at
the baseline and at the end of each treatment phase. As a
preference measure, at the end of the second treatment
phase patients were also asked to answer the Treatment
Preference Question (TPQ): "Which treatment regimen
did you prefer?" The options were on demand or
scheduled (three times per week).
Treatment emergent adverse events, defined as events
that first occurred or worsened after the baseline, were
recorded throughout the study period, and all
randomized patients were included in the safety analysis.
Statistical analyses were conducted on an
intent-to-treat basis, considering TPQ as the primary endpoint and
efficacy measures IIEF and SEP as secondary endpoints.
The one-sample z-test with a two-sided significance of
0.05 was used to analyze the null hypothesis that equal
proportions of patients prefer the on-demand and three
times per week dosing regimens of tadalafil at the TPQ.
Efficacy variables were evaluated by a cross-over
analysis of variance model, using P < 0.05 as a cut-off for
statistical significance. Protocol and informed consent
documents were approved by ethical review board at
each investigative site. The study was conducted in
accordance with the protocol, the ethical principles stated
in the Declaration of Helsinki 2002 and applicable laws.
3 Results
3.1 Patients
Out of 1 140 Italian patients signing the informed
consent, 1 058 completed the run-in phase and were
randomized to treatment. All patients answered the
preference question at the end of the second treatment phase.
A total of 137 patients discontinued the study early
(Figure 2). The most common reasons for early
discontinuation were adverse events (4.6%) and lack of
efficacy (2.3%) (Table 1).
Patients' baseline characteristics are reported in Table 2.
The mean age was 54.8 years, the average weight was
80.3 kg, with an average height of 172.9 cm, and 99.9%
were Caucasian. Approximately 74% of patients had an
ED history of 1 year or more and the baseline ED severity
was classified as moderate or severe in 58.2% of the
patients. The ED etiology was clinically determined by
investigators and reported as organic in 34.6%, mixed in
45.8% and psychogenic in 19.6% of patients.
Approximately one-quarter of the patients were
smokers and 40.7% of the patients consumed alcohol.
The mean number of doses per week in the three times per week and the on-demand regimen was 2.33
and 1.89, respectively (P < 0.001)
3.2 Primary endpoint analysis: preference
by TPQ
Of the 1 058 subjects who answered the TPQ, 561
(59.1%) chose the on-demand treatment regimen and 389 (40.9%), chose the three times per week regimen.
This same pattern of patient choice was observed
regardless of whether patients were randomly assigned to
the three times per week subgroup A (dosing Monday,
Wednesday and Friday) or B (dosing Tuesday, Thursday and Saturday), and regardless of the sequence of
cross-over treatment schedules (on-demand followed by
three times per week or the reverse). Furthermore, the
analysis of preference based on baseline characteristics
showed that preference was not dependent on the patients' age or the etiology, severity and duration of ED.
3.3 Secondary endpoint analyses: IIEF and SEP
The overall mean IIEF score significantly improved
compared to the baseline for both treatment regimens. A
sub-analysis of the IIEF domains showed similar
improvements for both regimens in all but in the Erectile Function
(IIEF-EF) domain, which improved from 14.80 at the
baseline to 24.67 with the on-demand regimen, and to
25.00 with the three times per week regimen
(P = 0.012) (Figure 3). The analysis of the single items of IIEF showed
that patients in the three times per week regimen scored
significantly better in the questions on intercourse
satisfaction (P = 0.012), maintenance ease
(P = 0.026), penetration ability
(P = 0.034), erection firmness
(P = 0.006) and erection frequency
(P = 0.034), whereas no difference was reported in the remaining questions (Figure 4).
Stratifying patients for baseline severity of ED showed
a higher efficacy of the on-demand regimen in patients
with mild ED, whereas the three times per week regimen
was more effective in patients with severe ED (Figure 5).
SEP questionnaire results are shown in Figure 6. In
response to the SEP3 question (Did your erection last
long enough for you to have successful intercourse?),
the mean per patient success rate improved from 19.6%
at the baseline to 72.9% at the endpoint for the
on-demand regimen, and from 19.0% to 75.9% for the three
times per week regimen.
In response to the SEP5 question (Were you
satisfied overall with this sexual experience?), the mean per
patient rate improved from 6.3% at the baseline to
63.0% at the endpoint for the on-demand regimen and from
6.2% to 66.0% for the three times per week regimen.
For all SEP questions the improvement reported with the
three times per week regimen was significantly higher
than that with the on-demand regimen.
3.4 Adverse events
Both treatment regimens were well tolerated and no
deaths were reported. Adverse events were rare and
generally mild and caused early discontinuation in 4.6%
of patients (Table 1). No significant difference in the
incidence of adverse was found comparing the two
treatment regimens (Table 3).
4 Discussion
The aim in the treatment of ED is to restore an
erection satisfaction for the needs of the patient. The PDE5
inhibitors are currently the first therapeutic line in ED
treatment, and all the three available agents, sildenafil,
vardenafil and tadalafil, are effective and safe [4_6].
Actually, there are no data supporting superiority for any
one of them in terms of efficacy or safety, and both
clinician and patient make their choice considering
several factors related to the sexual activity and the
preference of the patient and to the peculiar pharmacokinetic
characteristics of these drugs (e.g. the possible
interference with alcohol and food and the duration of clinical
effects).
As patient's reported outcome is the gold-standard
in efficacy evaluation, it is currently widely accepted that
patient's preference should be regarded as the leading
criterion in the treatment strategy [7, 8].
Several preference studies comparing PDE5 inhibitors have been
conducted, but for most of them the interpretation of the
results is affected by important design flaws, including
absence of randomization, non-equivalence of the doses
used for the compared drugs, questionable data analysis,
and period and carryover effects [9]. The SURE study
was a randomized, cross-over trial where two regimens
of the same drug were compared [3]. This study design
is the best choice for comparative studies, and adds
reliability to both the preference and efficacy results obtained.
The SURE study enrolled 4 262 patients in 14
European countries, and showed that tadalafil was equally
effective and well tolerated in both treatment regimens,
and that an unexpectedly high number of patients (42.2%)
preferred the novel three times per week treatment [3].
However, efficacy results showed a slightly higher
improvement in all SEP questions and in all but one IIEF
domains with the three times per week compared to the
on-demand regimen. Although statistically significant,
these differences were not considered clinically
significant by the authors because of the small numerical
improvement of the scores and the large sample size.
The present analysis of the Italian data subset
confirms that both regimens provide excellent efficacy and
tolerability, and that in the clinical practice the patient
could choose between the two alternative but equally
effective treatments according to his personal needs and
preference. However, the finding of a statistically higher
improvement in all SEP questions and in the IIEF-EF
domain score with the three times per week compared
to the on-demand regimen is also confirmed in the present
subsample, which is smaller and geographically more
homogeneous than the whole SURE study dataset. Furthermore, when patients were stratified for severity
of ED, a superiority of the three times per week regimen
in improving the IIEF-EF domain score was shown in
severe patients, whereas the on-demand regimen was
more effective in mild patients. However, this
difference was numerically small and hardly perceivable by
patients. This is confirmed by the preference data
analysis, showing that the baseline severity of ED could
not predict the preference pattern.
Although not big enough to be considered clinically
important, the statistically higher efficacy of the three
times per week regimen is meaningful from a
speculative viewpoint. It has recently been supposed that the
assumption of PDE5 inhibitors on a regular base,
providing at steady serum levels and a higher drug exposure,
might improve the endothelial function of the corpus
cavernosum, therefore enhancing erectile function
beyond that observed with the on-demand treatment [10].
In our study the mean number of doses per week assumed by patients was 2.33 and 1.89 in the three times
per week and the on-demand regimen, respectively
(P < 0.001).
Although this has not translated in a clinically higher
efficacy of the three times per week regimen in the
overall population in study, a wider, perhaps clinically
significant difference is evident in the subgroup of patients with
severe ED. It could be hypothesized, then, that severe
patient can benefit more than mild patients from the higher
exposure to tadalafil reported in the three times per week
regimen. This observation would support a
rehabilitative role of tadalafil three times per week in severe ED
and could open new interesting therapeutic perspectives
for the PDE5 inhibitors in the treatment of ED.
In conclusion, the analysis of the Italian dataset of
the SURE study confirms that tadalafil is effective and
well tolerated whether used as a traditional on-demand
treatment or in a novel three times per week regimen. In
the decision-making process that, through interaction
between clinician's guide and patient's preference, leads
to the selection of the optimal treatment of ED, these
observations provide a scenario where not only the drug
but also the treatment regimen can be chosen, further
increasing our ability to tailor treatment to an individual
patient's needs.
Acknowledgment
Christine Kuepfer, Sabine Weitckus, Lucio Varanese,
(Eli Lilly), Flavia Fascetti, Lapo Feri, Pierluigi Crisà (Eli
Lilly Italy) provided assistance with the study and in the
preparation of this manuscript.
References
1 Porst H, Padma-Nathan H, Giuliano F, Anglin G, Varanese L,
Rosen R. Efficacy of tadalafil for the treatment of erectile
dysfunction at 24 and 36 hours after dosing: a randomized
controlled trial. Urology 2003; 62: 121_5.
2 Porst H. IC351 (tadalafil, Cialis): update on clinical experience.
Int J Impot Res 2002; 14 (Suppl 1): S57_64.
3 Mirone V, Costa P, Damber JE, Holmes S, Moncada I, Van Ahlen
H, et al. An evaluation of an alternative dosing regimen with
tadalafil, 3 times/week, for men with erectile dysfunction: SURE
study in 14 European countries. Eur Urol 2005; 47: 846_54.
4 Brock GB, McMahon CG, Chen KK, Costigan T, Shen W,
Watkins V, et al. Efficacy and safety of tadalafil for the
treatment of erectile dysfunction: results of integrated analyses. J
Urol 2002; 168: 1332_6.
5 Hellstrom WJ, Gittelman M, Karlin G, Segerson T, Thibonnier
M, Taylor T, et al. Vardenafil for treatment of men with
erectile dysfunction: efficacy and safety in a randomized,
double-blind, placebo-controlled trial. J Androl 2002; 23: 763_71.
6 Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers
WD, Wicker PA, et al. Oral sildenafil in the treatment of
erectile dysfunction. N Engl J Med 1998; 338: 1397_404.
7 Hedelin H, Stroberg P. Treatment for erectile dysfunction
based on patient-reported outcomes: to every man the PDE5
inhibitor that he finds superior. Drugs 2005; 65: 2245_51.
8 Heaton JP, Hackett G, Savage D, Padley RJ. Patient choice is
critical in managing erectile dysfunction. Eur Urol 2002;
1(Suppl 1): 33_7.
9 Mulhall JP, Montorsi F. Evaluating preference trials of oral
phosphodiesterase 5 inhibitors for erectile dysfunction. Eur
Urol 2006; 49: 30_7.
10 Sommer F, Schulze W. Treating erectile dysfunction by
endothelial rehabilitation with phosphodiesterase 5 inhibitors.
World J Urol 2005; 23: 385_92. |